Generic medicament classification and limitation: common abbreviation without proprietary trade mark value did not justify extended demand.
A commonly used abbreviation of a drug name, without exclusive proprietary significance or trade-mark association, does not amount to a brand name, so the medicament was correctly treated as a generic product classifiable under Heading 3003.20 rather than a patent or proprietary medicament. The extended limitation period was also unavailable because the classification declaration and product label had been disclosed to the department, and no suppression of facts was shown; the demand was therefore time-barred. The duty-confirming order was set aside.
Issues: (i) Whether the medicament sold as "Acetyl Salicylic Acid Tablets IP 50 MG (ASA)" was a patent or proprietary medicament or a generic medicament classifiable under Heading 3003.20. (ii) Whether the demand for the extended period was sustainable.
Issue (i): Whether the medicament sold as "Acetyl Salicylic Acid Tablets IP 50 MG (ASA)" was a patent or proprietary medicament or a generic medicament classifiable under Heading 3003.20.
Analysis: The dispute turned on Chapter Note 2(ii) of Chapter 30, under which a patent or proprietary medicament must bear a name that is not specified in a pharmacopoeia or must bear a brand name in relation to which the user has a proprietary right. The abbreviation "ASA" was found to be a commonly used abbreviation for "Acetyl Salicylic Acid" and not a mark identifying the appellant exclusively. Since the abbreviation was widely used by others and did not indicate a proprietary connection in trade, it could not be treated as a brand name. The medicament was therefore regarded as sold under its generic name.
Conclusion: The classification under Heading 3003.20 was correct and the product was not a patent or proprietary medicament.
Issue (ii): Whether the demand for the extended period was sustainable.
Analysis: The classification declaration and the product label were filed with the department at the time of the change in packaging and marketing, so the relevant facts were already within departmental knowledge. In the absence of suppression of facts, the extended period could not be invoked.
Conclusion: The demand for the extended period was time-barred and not sustainable.
Final Conclusion: The order confirming duty was set aside, and the appeals succeeded on both merits and limitation.
Ratio Decidendi: A commonly used abbreviation of a generic drug name, without proprietary trade-mark significance or exclusive trade right, does not constitute a brand name for classifying a medicament as patent or proprietary; and where the relevant facts are disclosed to the department, the extended limitation period cannot be invoked absent suppression.
TaxTMI 
AI Drafter ✕
TaxTMI 
